Nhungamiro Ruzivo PaLenvatinib Yekenza - AASraw
MUTSVENE unoburitsa Cannabidiol (CBD) upfu uye Hemp Yakakosha Oiri muhuwandu!

Lenvatinib

 

  1. Nhoroondo YaLenvatinib
  2. Chii chinonzi Lenvatinib?
  3. Lenvatinib Maitiro ekuita
  4. Lenvatinib Inoshandiswei?
  5. Ndeapi Mativi Akakomba Ndingaone Iwe Paunoshandisa Lenvatinib?
  6. Lenvatinib Clinical Mhedzisiro (FDA Kubvumidzwa)
  7. Ndekupi kwandinofanira kuchengeta Lenvatinib?
  8. Zvakafanana Zvinodhaka: Lenvatinib Mesylate (CAS: 857890-39-2)
  9. Ndekupi Kwatinogona Kutenga Lenvatinib pamhepo?

 

Nhoroondo Ya Lenvatinib

Chikamu chekutanga chemakiriniki kutongwa nevarwere vegomarara chakaitwa muna2006. [8] Chikamu chechitatu chechitatu chekurapa kenza yehutachiona varwere yakatanga muna Kurume 2011

Lenvatinib akapiwa nherera chinzvimbo chemushonga yekurapa mhando dzakasiyana dzekenza yeutachiona isingapindure newairesi muUS neJapan muna2012 uye muEurope muna2013.

MunaFebruary 2015, iyo US FDA yakabvumidza lenvatinib yekurapa inofambira mberi, radioiodine Refractory kusiyanisa cancer yekenza. Muna Chivabvu 2015, European Medicines Agency (EMA) yakabvumidza mushonga wechiratidzo chimwe chete.

MunaMay 2016, iyo FDA yakazvibvumidza (zvakabatana neeverolimus) yekurapa kwepamberi renal cell carcinoma inotevera imwe yekutanga anti-angiogenic kurapwa.

Muna Nyamavhuvhu 2018, iyo FDA yakabvumidza lenvatinib yekurapa-yekutanga kurapa kwevanhu vane zvisingaonekwe hepatocellular carcinoma (HCC).

 

Chii Lenvatinib?

Lenvatinib (CAS:417716-92-8) ndeye receptor tyrosine kinase (RTK) inhibitor iyo inodzivisa iyo kinase zviitiko zvevascular endothelial grow factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), uye VEGFR3 (FLT4). Lenvatinib inodzivirirawo mamwe maRTK akave akabatanidzwa mune pathogenic angiogenesis, bundu kukura, uye kufambira mberi kwegomarara mukuwedzera kune avo akajairwa maseru mashandiro, kusanganisira fibroblast kukura factor (FGF) receptors FGFR1, 2, 3, uye 4; iyo platelet inotora kukura chinhu chinogamuchira alpha (PDGFRcy), KIT, uye RET. Aya ma-receptor tyrosine kinases (RTKs) ari musero membrane anoita chinzvimbo chakakosha mukumisikidza nzira dzekushambadzira kwemasaini dzakabatanidzwa mune zvakajairika kutonga kwema cell maitiro, sekuwedzera kwesero, kutama, apoptosis uye kusiyanisa, uye mune pathogenic angiogenesis, lymphogenesis, bundu kukura uye kuwedzera kenza. Kunyanya, VEGF yakaonekwa seyakakosha mutongi weese physiologic uye pathologic angiogenesis uye kuwedzera kutaura kweVEGF inosanganisirwa nehurombo kufungidzira mumhando zhinji dzekenza.

Lenvatinib inoratidzirwa yekurapa kwevarwere vane kwazvino kudzokororwa kana metastatic, inofambira mberi, radioactive iodine (RAI) -inotsoropodza kusiyanisa cancer yekenza. Vazhinji varwere vane gomarara remukaka vane fungidziro yakanaka kwazvo nekurapwa (98% 5 yemakore ekupona mwero) inosanganisira kuvhiyiwa uye kurapwa kwehomoni. Nekudaro, kune varwere vane RAI-inokanganisa kenza yehutachiona, sarudzo dzekurapa dzinogumira uye kufungidzira kwakashata, zvichitungamira mukumanikidza kwekuvandudzwa kwemamwe marapirwo akadai selenvatinib.

 

Lenvatinib Mechanism of action

Lenvatinib inogamuchira tyrosine kinase (RTK) inhibitor iyo inodzivisa zviitiko zvekinase zvevascular endothelial grow factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), uye VEGFR3 (FLT4). Lenvatinib inodzivirirawo mamwe maRTK akave akabatanidzwa mune pathogenic angiogenesis, bundu kukura, uye kufambira mberi kwegomarara mukuwedzera kune avo akajairwa maseru mashandiro, kusanganisira fibroblast kukura factor (FGF) receptors FGFR1, 2, 3, uye 4; iyo platelet inotora kukura chinhu chinogamuchira alpha (PDGFRcy), KIT, uye RET.

AASraw inyanzvi inogadzira Lenvatinib.

Ndokumbirawo ubaye pano kuti uwane ruzivo Cont Cont us

 

Chii Lenvatinib Yakashandiswa? 

❶ Lenvatinib inoshandiswa kurapa imwe mhando ye thyroid gomarara rakadzoka kana rakapararira kune dzimwe nhengo dzemuviri uye risingakwanise kurapwa neayadhi ine radioactive.

❷ Lenvatinib inoshandiswawo pamwe neeverolimus (Afinitor, Zortress) kurapa renal cell carcinoma (RCC, rudzi rwekenza inotangira muitsvo) muvanhu vakambowana kurapwa neimwe chemotherapy mishonga.

❸ Lenvatinib inoshandiswawo kurapa hepatocellular carcinoma (HCC; rudzi rwekenza yechiropa) iyo isingakwanise kurapwa nekuvhiya.

❹ Lenvatinib inoshandiswawo pamwe ne pembrolizumab (Keytruda) kurapa imwe mhando ye kenza yeiyo endometrium (lining yechibereko) iyo yakapararira kune zvimwe zvikamu zvemuviri kana kuwedzera munguva kana mushure mekurapwa nemakemikari mishonga kana isingakwanise kurapwa nekuvhiya kana radiation radiation.

V Lenvatinib ari mukirasi yemishonga inonzi kinase inhibitors. Inoshanda nekudzivirira chiito chepuroteni isina kujairika iyo inoratidza masero ekenza kuti iwande. Izvi zvinobatsira kumisa kupararira kwemasero ekenza.

 

chii Spano Ekukanganisa May ini Notice When Iwe Unoshandisa Lenvatinib?

Zvimwe zvinokanganisa zvaunofanira kuudza chiremba wako kana nyanzvi yehutano nekukurumidza sezvazvinogona:

▪ kugadzikana sekuputika kweganda, kuvaviwa kana mikoko, kuzvimba kwechiso, miromo, kana rurimi

▪ kunetseka kufema

▪ kurwadziwa pachipfuva kana kuti kurova mbichana

▪ dzungu

▪ kunzwa kunge wakaneta kana kushaya musoro, unodonha

▪ kutemwa nemusoro

▪ BP

▪ pfari

▪ zviratidzo nezviratidzo zvekubuda ropa sveropa kana nhema, zvituru zvekumira; weti tsvuku kana nhema-shava; kupfira ropa kana zvinhu zvakasvibira zvinoita kunge kofi nzvimbo; mavara matsvuku paganda; kupwanya kusingawanzo kana kubuda ropa kubva muziso, matadza, kana mhino

▪ zviratidzo nezviratidzo zvekuchinja kune njodzi mukurova kwemoyo kana kurira kwemoyo sekurwadziwa pachipfuva; dzungu; nekukurumidza kana kusajairika kurova kwemoyo; palpitations; kunzwa kupera simba kana kuvezwa musoro, kudonha; matambudziko ekufema

▪ zviratidzo nezviratidzo zvekukuvara kweitsvo sekutambudzika kupfuudza weti kana shanduko muuwandu weti

▪ zviratidzo nezviratidzo zvekukuvara kwechiropa kunge weti yakasviba kana yeti shava; kurwara zvakanyanya kana zviratidzo zvakaita sefuru; zvituru-zvine zvituru; kurasikirwa nenzara; kusvotwa; kurudyi kwepamusoro dumbu kurwadziwa; zvisina kujairika kushaya simba kana kuneta; yero yeziso kana ganda

▪ zviratidzo nezviratidzo zvepasi pasi potasiyamu senge mhasuru dzinokomba kana kurwadziwa kwemhasuru; kurwadziwa muchipfuva; dzungu; kunzwa kupera simba kana kuvezwa musoro, kudonha; palpitations; matambudziko ekufema; kana nekukurumidza, kurova kwemoyo zvisina kujairika

▪ zviratidzo uye zviratidzo zvekurohwa senge shanduko pane maonero; kuvhiringidzika; kunetseka kutaura kana kunzwisisa; kutemwa nemusoro kwakakomba; kamwe kamwe kupera kana kushaya simba kwechiso, ruoko kana gumbo; kunetseka kufamba; dzungu; kurasikirwa kwechiyero kana kubatana

▪ kurwadziwa nemudumbu

Kuzvimba makumbo kana makumbo

▪ asina simba kana aneta zvisingaite

 

Mhedzisiro mhedzisiro iyo inowanzo isingade kurapwa (taurira chiremba wako kana nyanzvi yehutano kana vachiramba kana vachinetsa):

▪ manyoka

▪ kurwadza kwemajoini

▪ kushaya nzara

▪ maronda emuromo

▪ kurwadziwa nemhasuru

▪ kusvotwa, kurutsa

▪ kuonda

Urongwa urwu hunogona kusatsanangura zvese zvinogona kuitika mhedzisiro. Dana chiremba wako kuti akupe mazano ekurapa nezvemigumisiro. Unogona kuzivisa mhedzisiro kuDAA pa1-800-FDA-1088.

 

Lenvatinib

 

Lenvatinib Clinical Results(FDA Kubvumidzwa)

The Kubvumirwa kweFDA yeLenvatinib yaive yakavakirwa pane multicenter, yakasarudzika, yakapofumadza-bofu, inodzorwa-placebo-inodzorwa muedzo mune makumi matatu nemaviri zvidzidzo zvine kwazvino kudzokororwa kana metastatic radioactive iodine-inoratidzira kusiyaniswa thyroid kenza uye radiographic humbowo hwekuwedzera kwechirwere mukati memwedzi gumi nemaviri kusati kwaitika, kwakasimbiswa neyakavanzika radiologic ongororo. Iwo masomo akagashira Lenvatinib 12 mg kamwe zuva nezuva (n = 24) kana placebo (n = 261) kudzamara chirwere chichiwedzera. Mhedzisiro yekudzidza yakaratidza Lenvatinib-yakarapwa nyaya yakararama wepakati pemwedzi 131 pasina chirwere chavo chichienderera mberi (kufambira mberi-kusununguka kwehupenyu), zvichienzaniswa neyemukati memwedzi 18.3 yezvidzidzo zvakagamuchira placebo. Pamusoro pezvo, 3.6% yezvidzidzo zvakarapwa naLenvatinib yakaona kudzikiswa kwemarara, zvichienzaniswa ne65% yezvidzidzo zvakagamuchira placebo.

AASraw inyanzvi inogadzira Lenvatinib.

Ndokumbirawo ubaye pano kuti uwane ruzivo Cont Cont us

 

Ndekupi kwandinofanira kuchengeta Lenvatinib?

Chengetedza urege kusvika kune vana.

Chengetedza pakati pe20 kusvika 25 degrees C (68 uye 77 degrees F). Kanda chero mushonga usina kushandiswa mushure mekuguma kwezuva.

ONA: Iri pepa ipfupiso. Inogona kunge isingafukidze zvese zvinogona kuitika. Kana iwe uine mibvunzo nezve uyu mushonga, taura nachiremba wako, wemishonga, kana mutapi wezvehutano.

 

Zvimwe Zvinodhaka: Lenvatinib Mesylate (CAS: 857890-39-2)

Lenvatinib mesylate (CAS: 857890-39-2) inogadzirwa, inowanika mumuromo inhibitor yevascular endothelial grow factor receptor 2 (VEGFR2, inozivikanwawo seKDR / FLK-1) tyrosine kinase ine basa rinogona kuita antineoplastic. E7080 inovhara VEGFR2 activation neVEGF, zvichikonzera kuvharika kweiyo VEGF receptor chiratidzo transduction nzira, yakaderedza vascular endothelial cell kutama uye kuwanda, uye vascular endothelial cell apoptosis.

Lenvatinib mesylate methanesulfonate munyu unowanikwa nekuita lenvatinib ine imwe molar yakaenzana nemethanesulfonic acid. Iyo multi-kinase inhibitor uye nherera zvinodhaka zvinoshandiswa (seyayo mesylate munyu) yekurapa mhando dzakasiyana dzekenza yeutachiona isingapindure kune radioiodine. Iine basa seEC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, fibroblast growth factor receptor anopikisa, nherera zvinodhaka, vascular endothelial growth factor receptor antagonist uye antineoplastic mumiriri. Iyo ine lenvatinib (1+).

 

Lenvatinib mesylate inogamuchirwa kuti ishandiswe yega kana pamwe nemimwe mishonga yekurapa:

♦ Endometrial carcinoma iyo yakafambira mberi uye yakawedzera kuwedzera mushure meimwe nzira dzokurapa. Iyo inoshandiswa ne pembrolizumab mune varwere vane kenza isiri microsatellite kusagadzikana-yakakwira (MSI-H) kana kusakwana kwekugadzirisa kushomeka (dMMR) uye haigone kurapwa nekuvhiya kana radiation radiation.

♦ Hepatocellular carcinoma (rudzi rwegomarara rechiropa). Inoshandiswa sekutanga-kurapwa kurapwa mune varwere vane chirwere chisingakwanise kubviswa nekuvhiyiwa.

Al Renal cell carcinoma (rudzi rwegomarara reitsvo) iro rapfuura. Inoshandiswa neeverolimus mune varwere vakatowana angiogenesis inhibitor therapy.

Cancer Kenza yeThyroid mune vamwe varwere vane chirwere chinofambira mberi, chinodzokororwa, kana chemastasta chisingapindure kurapwa neayodini ine radioactive.

Uku kushandiswa kunotenderwa pasi peiyo FDA's Accelerated Approval Chirongwa. Semamiriro ekubvumidzwa, yekusimbisa kutongwa (s) inofanirwa kuratidza kuti lenvatinib mesylate inopa kiriniki kubatsirwa mune ava varwere. Lenvatinib mesylate iri kudzidziswawo mukurapa mamwe marudzi ekenza.

 

Ndekupi Kwatinogona Kutenga Lenvatinib Online?

Kune vazhinji vatengesi / vagadziri velenvatinib poda mumusika, kutsvaga chaiko kwakakosha kwazvo kuvanhu vese vanoda chigadzirwa ichi nekukurumidza. Kana isu tasarudza kutenga lenvatinib powder mumusika, tinofanirwa kudzidza rumwe ruzivo nezvazvo, kuziva mashandisiro uye mashandiro ekuita, chero njodzi patinotora lenvatinib powder…. Uye zvakare, mutengo uye mhando zvinofanirwa kuve zvatinonetsekana tisati tazvitenga.

Mushure mekunge taongorora dhata kubva kumusika, tichienzanisa vatengesi vazhinji, AASraw inotarisa sarudzo dzakanaka kune avo vanhu vanoda kutenga zvakawanda lenvatinib upfu, kugadzirwa kwavo kwaidzorwa zvakanyanya pasi peCGMP mamiriro, hunhu hunogona kuteverwa chero nguva uye ivo vangangopa ese miedzo yekuyedza kana iwe ukairaira. Kana iri lenvatinib poda inodhura / mutengo, inofanirwa kuve nemusoro, mumaziso angu. Nekuti ini ndawana mitengo yakawanda kubva kune vakasiyana vatengesi, zvichienzaniswa nehunhu, ndinofunga aasraw ichave isiri yakaipa sarudzo.
Kuti uwane mamwe mashoko, gamuchira kutaura neAASraw!

 

Reference

[1] H. Erdem, C. Gündogdu, naS S. Üipal, "Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma," Ongororo uye Molecular Pathology, vol. 90, kwete. 3, mapeji 312–317, 2011.

[2] M. Yagi, S. Kato, Y. Kobayashi et al., "Selective inhibition yeplatelet-yakatorwa kukura chinhu (PDGF) receptor autophosphorylation uye PDGF-mediated zviitiko zvemaseru neinobva kuquinoline," Ongororo yeSero Ongororo, vol. 234, kwete. 2, mapeji 285–292, 1997.

[3] P. Soares, J. Lima, A. Preto et al., "Genetic shanduko mune zvisina kusiyaniswa uye zvisina kukodzera utachiona carcinomas," Izvozvi. Genomics, vol. 12, kwete. 8, mapeji 609-617, 2011.

[4] MM Moura, BM Cavaco, V. Leite. RAS proto-oncogene mune medullary thyroid carcinoma. Endocr Relat Kenza, 22 (5) (2015), mapeji R235-R252.

[5] BR Haugen, SI Sherman Kubudirira kunosvika kuvarwere vane chirwere chekenza chetachiona chakasimudzwa. Endocr Rev, 34 (3) (2013), mapeji 439-455.

[6] M. Xing, D. Clark, H. Guan, uye al. BRAF mutation kuyedzwa kweiyo thyroid yakanaka-tsono aspiration biopsy specimens ye preoperative njodzi stratification mune papillary thyroid cancer J Clin Oncol, 27 (18) (2009), mapeji 2977-2982.

[7] SR Wedge, DJ Ogilvie, M. Dukes, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, uye kukura kwehuremu zvichitevera kutonga kwemuromo. Cancer Res, 62 (16) (2002), mapeji 4645-4655.

[8] SI Sherman, EEW Cohen, P. Schoffski, uye al. Kubudirira kwecabozantinib (Cabo) mune medullary cancer kenza (MTC) varwere vane RAS kana RET mutations: Mhedzisiro kubva muchikamu chechitatu chekudzidza [abstract]. J Clin Oncol, 31 (15 Suppl.) (2013) abstr 6000.

[9] SI Sherman, LJ Kuberekwa, JP Droz, et al. Motesanib diphosphate mukufambira mberi kusiyanisa kenza yehutachiona. N Engl J Med, 359 (1) (2008), mapeji 31-42.

[10] K. Okamoto, K. Kodama, K. Takase, et al. Antitumor zviitiko zveiyo yakanangidzirwa multi-tyrosine kinase inhibitor lenvatinib (E7080) inopesana neRET gene fusion-inotyairwa mamodheru mamodheru. Cancer Lett, 340 (1) (2013), mapeji 97-103.

[11] E. Cabanillas, M. Schlumberger, B. Jarzab, et al. Chikamu chechipiri chekuyedzwa kwelenvatinib (E2) mune yakakwira, inofambira mberi, radioiodine-inoratidzira, inosiyanisa cancer yekenza. 7080), mapeji 121-16.

0 zvaanofarira
1184 Views

Ungazvidyawo kufanana

Comments dzakavharika.